Screener
Palvella Therapeutics PVLA Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash used in operating activities | (10,864) | (6,768) |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Purchase of marketable securities | (55,440) | — |
| Net cash used in investing activities | (55,440) | — |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Payment of transaction costs in connection with Reverse Merger | — | (1,269) |
| Proceeds from issuance of common stock in connection with equity financing | 230,000 | — |
| Payment of financing cost in connection with equity financing | (14,247) | — |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's investing cash flow?
- Palvella Therapeutics (PVLA) reported investing cash flow of -$55.44M in Q1 2026.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Palvella Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude